These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28653286)

  • 21. Preclinical assessments of vaginal microbicide candidate safety and efficacy.
    Fernández-Romero JA; Teleshova N; Zydowsky TM; Robbiani M
    Adv Drug Deliv Rev; 2015 Sep; 92():27-38. PubMed ID: 25543007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent work on vaginal rings containing antiviral agents for HIV prevention.
    Spence P; Bhatia Garg A; Woodsong C; Devin B; Rosenberg Z
    Curr Opin HIV AIDS; 2015 Jul; 10(4):264-70. PubMed ID: 26049952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specific microbicides in the prevention of HIV infection.
    Kelly CG; Shattock RJ
    J Intern Med; 2011 Dec; 270(6):509-19. PubMed ID: 21917029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges.
    Garg S; Tambwekar KR; Vermani K; Kandarapu R; Garg A; Waller DP; Zaneveld LJ
    AIDS Patient Care STDS; 2003 Aug; 17(8):377-99. PubMed ID: 13678540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Women's interest in vaginal microbicides.
    Darroch JE; Frost JJ
    Fam Plann Perspect; 1999; 31(1):16-23. PubMed ID: 10029928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances on anti-HIV vaginal delivery systems development.
    Antimisiaris SG; Mourtas S
    Adv Drug Deliv Rev; 2015 Sep; 92():123-45. PubMed ID: 25858666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
    Notario-Pérez F; Ruiz-Caro R; Veiga-Ochoa MD
    Drug Des Devel Ther; 2017; 11():1767-1787. PubMed ID: 28670111
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recommendations for the development of vaginal microbicides. International Working Group on Vaginal Microbicides.
    AIDS; 1996 Jul; 10(8):1-6. PubMed ID: 8828760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The "House of Quality for Behavioral Science"-a user-centered tool to design behavioral interventions.
    Mullane SL; Epstein DR; Buman MP
    Transl Behav Med; 2019 Jul; 9(4):810-818. PubMed ID: 30099555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microbicides: a new frontier in HIV prevention.
    McGowan I
    Biologicals; 2006 Dec; 34(4):241-55. PubMed ID: 17097303
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formulation and delivery of anti-HIV rectal microbicides: advances and challenges.
    Nunes R; Sarmento B; das Neves J
    J Control Release; 2014 Nov; 194():278-94. PubMed ID: 25229988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Microbicides to prevent heterosexual transmission of HIV: ten years down the road.
    van de Wijgert J; Coggins C
    BETA; 2002; 15(2):23-8. PubMed ID: 12064303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Top stories of 2008. No good news yet on anti-HIV microbicides.
    Chimienti SN
    AIDS Clin Care; 2009 Jan; 21(1):4. PubMed ID: 19222153
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Translational paradigms in pharmacology and drug discovery.
    Mullane K; Winquist RJ; Williams M
    Biochem Pharmacol; 2014 Jan; 87(1):189-210. PubMed ID: 24184503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acceptability of a non-woven device for vaginal drug delivery of microbicides or other active agents.
    Joanis CL; Hart CW
    AIDS Behav; 2010 Jun; 14(3):600-6. PubMed ID: 20049522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microbicides for the prevention of sexually transmitted HIV infection.
    Karim QA; Baxter C
    Expert Rev Anti Infect Ther; 2013 Jan; 11(1):13-23. PubMed ID: 23428099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Male Partner Influence on Women's HIV Prevention Trial Participation and Use of Pre-exposure Prophylaxis: the Importance of "Understanding".
    Montgomery ET; van der Straten A; Stadler J; Hartmann M; Magazi B; Mathebula F; Laborde N; Soto-Torres L
    AIDS Behav; 2015 May; 19(5):784-93. PubMed ID: 25416076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets.
    Garg S; Goldman D; Krumme M; Rohan LC; Smoot S; Friend DR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S19-29. PubMed ID: 21109064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Developing a point-of-care electronic medical record system for TB/HIV co-infected patients: experiences from Lighthouse Trust, Lilongwe, Malawi.
    Tweya H; Feldacker C; Gadabu OJ; Ng'ambi W; Mumba SL; Phiri D; Kamvazina L; Mwakilama S; Kanyerere H; Keiser O; Mwafilaso J; Kamba C; Egger M; Jahn A; Simwaka B; Phiri S
    BMC Res Notes; 2016 Mar; 9():146. PubMed ID: 26945749
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expanding the domain of drug delivery for HIV prevention: exploration of the transdermal route.
    Puri A; Sivaraman A; Zhang W; Clark MR; Banga AK
    Crit Rev Ther Drug Carrier Syst; 2017; 34(6):551-587. PubMed ID: 29256837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.